Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Madrigal Pharmaceuticals Inc MDGL

Healthcare Biotechnology
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-ß (THR-ß) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic... see more

Recent & Breaking News (NDAQ:MDGL)

Madrigal Pharmaceuticals to Present Secondary Analyses of Data from Phase 2 NASH Study of Resmetirom and Symposium at the Digital International Liver Congress(TM) 2020

GlobeNewswire August 26, 2020

Madrigal Pharmaceuticals Reports 2020 Second Quarter Financial Results and Highlights

GlobeNewswire August 6, 2020

Madrigal Pharmaceuticals Reports 2020 First Quarter Financial Results and Highlights

GlobeNewswire May 7, 2020

Madrigal MAESTRO Phase 3 NASH Trials Continue without Protocol Modifications; New Data Demonstrate that Reductions in Liver Fat Achieved by Resmetirom Predict NASH Resolution and Fibrosis Reduction

GlobeNewswire April 14, 2020

Madrigal Pharmaceuticals Reports 2019 Fourth Quarter and Full Year Financial Results and Highlights

GlobeNewswire February 26, 2020

Madrigal Pharmaceuticals Announces First Patient Dosed in MAESTRO-NAFLD-1, a Second Phase 3 Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Resmetirom (MGL-3196) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Presumed NASH (NASH/NAFLD (non-alcoholic fatty liver disease))

GlobeNewswire December 18, 2019

Madrigal Pharmaceuticals Announces Secondary Offering of 1,200,000 Shares of Common Stock

GlobeNewswire December 10, 2019

Madrigal Pharmaceuticals Announces Publication in The Lancet of Positive Phase 2 Results for Resmetirom (MGL-3196) for the Treatment of Non-alcoholic Steatohepatitis (NASH)

GlobeNewswire November 11, 2019

Madrigal Pharmaceuticals Reports 2019 Second Quarter Financial Results and Highlights

GlobeNewswire August 7, 2019

Madrigal Pharmaceuticals Promotes Rebecca Taub, M.D., Chief Medical Officer and Executive Vice President of Research & Development, to Newly Created Position of President of Research & Development

GlobeNewswire July 11, 2019

Madrigal Pharmaceuticals Announces Appointment of Jim Daly to Board of Directors

GlobeNewswire July 2, 2019

Madrigal Pharmaceuticals to Present at Upcoming Investment Conferences

GlobeNewswire June 4, 2019

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by the Certain Officers and Directors of Madrigal Pharmaceuticals, Inc.

GlobeNewswire May 15, 2019

Madrigal Pharmaceuticals Reports 2019 First Quarter Financial Results and Highlights

GlobeNewswire May 8, 2019

Madrigal Pharmaceuticals to Present Additional Analyses of Data from The Phase 2 NASH Study with MGL-3196 (resmetirom) at The International Liver Congress™ 2019

GlobeNewswire April 8, 2019

Madrigal Pharmaceuticals Initiates Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis a

GlobeNewswire March 28, 2019

Madrigal Pharmaceuticals Reports 2018 Fourth Quarter and Full Year Financial Results and Highlights

GlobeNewswire February 27, 2019

Report: Exploring Fundamental Drivers Behind CASI Pharmaceuticals, Booking, Enstar Group, Madrigal Pharmaceuticals, Dermira, and Kaiser Aluminum — New Horizons, Emerging Trends, and Upcoming Developments

GlobeNewswire November 28, 2018

Phase 2 Results for Madrigal’s MGL-3196 in Non-Alcoholic Steatohepatitis (NASH) Presented during Presidential Plenary Clinical Session of The Liver Meeting® 2018

GlobeNewswire November 12, 2018

Madrigal Pharmaceuticals Reports 2018 Third Quarter Financial Results and Highlights Upcoming Clinical Events

GlobeNewswire November 6, 2018